BiotechTube

BEAM-103 + Placebo Comparator

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Subjects

Conditions

Healthy Subjects, Healthy Participant Study

Trial Timeline

Oct 27, 2025 → May 29, 2026

NCT ID
NCT07304791

About BEAM-103 + Placebo Comparator

BEAM-103 + Placebo Comparator is a phase 1 stage product being developed by Beam Therapeutics for Healthy Subjects. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07304791. Target conditions include Healthy Subjects, Healthy Participant Study.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07304791Phase 1Recruiting

Competing Products

20 competing products in Healthy Subjects

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Beam Therapeutics

BEAM-201Phase 1/2
36
BEAM-101Phase 1/2
36
BEAM-301: Single dose of BEAM-301 administered by IVPhase 1/2
36
BEAM-302Phase 1/2
36
Allogeneic anti-CD7 CAR-T cells (BEAM-201)Phase 1
28